Last €62.54 EUR
Change Today +0.18 / 0.29%
Volume 137.1K
UCB On Other Exchanges
Symbol
Exchange
EN Brussels
OTC US
OTC US
Frankfurt
As of 11:35 AM 11/27/14 All times are local (Market data is delayed by at least 15 minutes).

Transactions by UCB SA (UCB) in the last 6 months

Announced 11/7/14
1.53B for Kremers Urban Pharmaceuticals Inc.
Merger/Acquisition

Advent International Corporation and Avista Capital Holdings, L.P. signed an agreement to acquire Kremers Urban Pharmaceuticals Inc. from UCB SA (ENXTBR:UCB) for $1.5 billion in cash on November 7, 2014. The deal financing is provided by Credit Suisse Securities LLC, Morgan Stanley & Co. LLC, Goldman, Sachs & Co and Jefferies LLC. Brian Markison, a healthcare Industry Executive at Avista, will become President and Chief Executive Officer of Kremers Urban. The transaction ...
Read More


UCB's price was unchanged after the transaction was announced on 11/7/14.
Investor / Buyer
Advent International Corporation
Avista Capital Holdings, L.P.
Creditor / Lender
UCB SA
 
Announced 09/19/14
8.00M for Dermira, Inc.
Private Placement

Dermira, Inc. (NasdaqGS:DERM) announced that it has entered into a common stock purchase agreement for the private placement of 468,750 shares at a price of $16 per share for gross proceeds of $7,500,000 on September 19, 2014.The company will not pay any underwriting discounts or commissions with respect to the shares. The securities will be issued to the existing investor UCB SA. The investor invested through its affiliate, UCB Pharma S.A.


UCB's price was unchanged after the transaction was announced on 09/19/14.
Investor / Buyer
UCB SA
 
Announced 08/15/14
51.00M for Dermira, Inc.
Private Placement

Dermira Inc. announced a private placement of 30,722,886 shares of series C convertible preferred stock at $1.66 per share for gross proceeds of $50,999,990.76 on August 15, 2014. The preferred stock issued in the transaction has a par value of $0.001 per share. The company announced that each share of preferred stock is convertible into one share of common stock of the company at a price of $1.66 per share and holds a dividend payment of $0.13 per share per annum. The ...
Read More


UCB's price was unchanged after the transaction was announced on 08/15/14.
Investor / Buyer
Aisling Capital LLC
Apple Tree Partners
Bay City Capital LLC
Canaan Partners
Fidelity Advisor Series VII - Fidelity Advisor Biotechnology Fund
Fidelity Investments
New Enterprise Associates
Rock Springs Capital
Sabby Capital
UCB SA
Legal Advisor
Fenwick & West, LLP
 
Announced 07/3/14
5.00M for Dermira, Inc.
Private Placement

Dermira Inc. announced that it has received $5 million in equity funding from new investor UCB SA on July 3, 2014. The investor has made a commitment to invest up to an additional $15 million in the future equity findings.


UCB's price was unchanged after the transaction was announced on 07/3/14.
Investor / Buyer
UCB SA
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UCB:BB €62.54 EUR +0.18

UCB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grifols SA €36.32 EUR +0.71
Hospira Inc $60.29 USD +0.21
Lonza Group AG SFr.112.00 CHF +3.80
Sigma-Aldrich Corp $136.53 USD -0.02
Valspar Corp/The $82.70 USD -0.34
View Industry Companies
 

Industry Analysis

UCB

Industry Average

Valuation UCB Industry Range
Price/Earnings 37.7x
Price/Sales 3.1x
Price/Book 2.3x
Price/Cash Flow 38.9x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UCB SA, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.